Evidence map›Paper›PMID 41821884›Full record

ArticleFrontiers in oncology2026

Genomic profiling and HER2-targeted therapy: a case series of Chinese salivary duct carcinoma patients and its clinical implications.

Xiang Huang, Wei Yu, Xiaomo Li, Boning Cai, Baolin Qu, Jing Chen, Pei Zhang, Xinrui Chen, Yanli Liu, Shengqiang Feng and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Xiang Huang *Department of Radiation Oncology, Senior Department of Oncology, the First Medical Center of PLA General Hospital, Beijing, China.
Wei Yu *Department of Radiation Oncology, Senior Department of Oncology, the First Medical Center of PLA General Hospital, Beijing, China.
Xiaomo Li *Genetron Health (Beijing) Technology, Co. Ltd, Beijing, China.
Boning CaiDepartment of Radiation Oncology, Senior Department of Oncology, the First Medical Center of PLA General Hospital, Beijing, China.
Baolin QuDepartment of Radiation Oncology, Senior Department of Oncology, the First Medical Center of PLA General Hospital, Beijing, China.
Jing ChenDepartment of Radiation Oncology, Senior Department of Oncology, the First Medical Center of PLA General Hospital, Beijing, China.
Pei ZhangDepartment of Radiation Oncology, Senior Department of Oncology, the First Medical Center of PLA General Hospital, Beijing, China.
Xinrui ChenDepartment of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, Beijing, China.
Yanli LiuDepartment of Radiation Oncology, Senior Department of Oncology, the First Medical Center of PLA General Hospital, Beijing, China.
Shengqiang FengHealth Service Department of the Guard Bureau, The Joint Staff Department, Beijing, China.
Lin GuiDepartment of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, Beijing, China.
Fang LiuDepartment of Radiation Oncology, Senior Department of Oncology, the First Medical Center of PLA General Hospital, Beijing, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Purpose: Salivary duct carcinoma (SDC) is a rare and aggressive subtype of salivary gland cancers (SGCs). Currently, there is no approved targeted therapy for this devastating disease. This study aimed to identify actionable genomic alterations in Chinese patients with SDC and explore the clinical efficacy of human epidermal growth factor receptor 2 (HER2)-targeted therapies in this population. Methods: Somatic and genomic DNA were isolated from SDC samples and the corresponding peripheral blood controls, respectively. To explore the potential of targeted therapy, next-generation sequencing (NGS) was used to identify genomic alterations, especially mutations with clinical significance. Results: The most prevalent driver mutations in this SDC cohort are Conclusion: Our work underscores the potential of genomic profiling to guide precision therapy in SDC, with HER2-targeted treatments offering promising therapeutic avenues.

Indexed as

driver mutationHER2-targeted therapypertuzumabpyrotinibsalivary duct carcinomatrastuzumab

Identifiers

PMID41821884
PMCPMC12975472

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.